Back to results
US 12,667,566 B2Granted
Combination therapy of GPR119 agonists and DPP-4 inhibitors
AssigneeMankind Pharma Ltd.
InventorsRakesh Iswar Patil, Sazid Ali, Srinivasa Reddy Bapuram, Santosh Kumar Rai, Anil Kumar
Life of this patent
Estimating the term…
Abstract
The present invention relates to combinations of GPR119 receptor agonists with DPP-4 inhibitors and their use thereof for treating or preventing cardiovascular and metabolic disorders, including diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), NAFL, NASH, dyslipidemia, and related disorders thereto.
Claims7
A pharmaceutical combination comprising:
- (a) a GPR119 agonist of Formula IA:
- tautomers thereof, stereoisomers thereof, and pharmaceutically acceptable salts thereof in a range from 0.001 mg to 1000 mg;
- and
- (b) sitagliptin or a pharmaceutically acceptable salt thereof in a range from 25 mg to 200 mg.
1 more element
A kit comprising:
- (a) a first component comprising a GPR119 agonist of Formula IA:
- tautomers thereof, stereoisomers thereof, and pharmaceutically acceptable salts thereof in a range from 0.001 mg to 1000 mg;
- (b) a second component comprising sitagliptin or a pharmaceutically acceptable salt thereof in a range from 25 mg to 200 mg, and
- (c) optionally one or more pharmaceutically acceptable carriers.
1 more element
Dependencies are inferred from the claim text.